Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018
Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation at ASCO-GI 2018, taking place 18-20th of January in San Francisco, USA. The accepted abstract describes interim results from the ongoing ISO-CC-005 study in which Modufolin® is administrated in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab.Isofol Medical AB (publ) announces that an abstract has been accepted for presentation at next year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (